Business, energy, technology, markets and global industry news from Business News Today

cancer supportive care

PharmaDeviceNews cancer supportive care
Representative image: Clinical analytics and gastrointestinal imaging scene reflecting Seres Therapeutics’ SER-155 data in checkpoint inhibitor-related enterocolitis and the emerging role of microbiome therapeutics in cancer supportive care.
Pharma & Biotech

Why SER-155 could become a key clinical catalyst for Seres Therapeutics

Seres Therapeutics Inc. (Nasdaq: MCRB) has reported early clinical data for SER-155 in immune checkpoint inhibitor-related enterocolitis, a gastrointestinal immune-related adverse event that can interrupt cancer immunotherapy. The investigator-sponsored study evaluated the live biotherapeutic in 15 patients with moderate to severe disease and showed an immunosuppressive free clinical response in 80 percent of participants at

Read More
Representative image showing radiation-induced skin toxicity, a growing challenge in oncology care. Hoth Therapeutics is targeting this unmet need with HT-001, aiming to redefine supportive treatment in oncodermatology.
Pharma & Biotech

Hoth Therapeutics makes strategic IP move to tackle radiation and targeted therapy skin toxicities

Hoth Therapeutics, Inc. has filed two provisional U.S. patents for its investigational therapy HT-001, aiming to address skin toxicities caused by radiation and targeted cancer therapies. The dual filings mark a deliberate expansion into oncology-adjacent dermatology, establishing a new intellectual property footprint around treatment-induced skin damage, including adverse effects linked to menin inhibitors. This signals

Read More